Ravendra Garg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/77439/publications.pdf

Version: 2024-02-01

		516561	501076
35	822	16	28
papers	citations	h-index	g-index

35	35	35	1075
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	225Acâ€labeled CD33â€targeting antibody reverses resistance to Bclâ€2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Medicine, 2021, 10, 1128-1140.	1.3	25
2	Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy. Oncotarget, 2020, 11, 3571-3581.	0.8	4
3	Innate immune protection from pneumonia virus of mice induced by a novel immunomodulator is prolonged by dual treatment and mediated by macrophages. Antiviral Research, 2019, 171, 104594.	1.9	3
4	Metabolomic and Immunological Profiling of Respiratory Syncytial Virus Infection after Intranasal Immunization with a Subunit Vaccine Candidate. Journal of Proteome Research, 2019, 18, 1145-1161.	1.8	15
5	Selection of adjuvants for vaccines targeting specific pathogens. Expert Review of Vaccines, 2019, 18, 505-521.	2.0	68
6	Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T. Biology of Blood and Marrow Transplantation, 2019, 25, S194.	2.0	0
7	Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs. Antiviral Research, 2019, 162, 54-60.	1.9	7
8	Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy. Blood, 2019, 134, 5601-5601.	0.6	1
9	The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages. Vaccine, 2018, 36, 2326-2336.	1.7	13
10	The Major Tegument Protein of Bovine Herpesvirus 1, VP8, Interacts with DNA Damage Response Proteins and Induces Apoptosis. Journal of Virology, 2018, 92, .	1.5	14
11	A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3. Antiviral Research, 2018, 158, 78-87.	1.9	12
12	Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle. Vaccine, 2017, 35, 3466-3473.	1.7	16
13	A novel combination adjuvant platform for human and animal vaccines. Vaccine, 2017, 35, 4486-4489.	1.7	40
14	Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus. Human Vaccines and Immunotherapeutics, 2017, 13, 2894-2901.	1.4	11
15	A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Virology, 2016, 499, 288-297.	1.1	17
16	Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity. Vaccine, 2016, 34, 5114-5124.	1.7	15
17	Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal pneumonia virus of mice. Antiviral Research, 2016, 135, 108-119.	1.9	7
18	Immunostimulatory potential and proteome profiling of Leishmania donovani soluble exogenous antigens. Parasite Immunology, 2015, 37, 368-375.	0.7	11

#	Article	IF	Citations
19	Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients. Clinical and Experimental Immunology, 2015, 180, 484-498.	1.1	24
20	Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. Journal of General Virology, 2014, 95, 301-306.	1.3	47
21	Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. Journal of General Virology, 2014, 95, 1043-1054.	1.3	39
22	The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle. Vaccine, 2014, 32, 6758-6764.	1.7	31
23	Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon. Virology, 2012, 432, 271-276.	1.1	9
24	The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. Expert Review of Vaccines, 2012, 11, 1441-1457.	2.0	27
25	Leishmania infantum Amastigotes Enhance HIV-1 Production in Cocultures of Human Dendritic Cells and CD4+ T Cells by Inducing Secretion of IL-6 and TNF-Î±. PLoS Neglected Tropical Diseases, 2009, 3, e441.	1.3	30
26	Intracellular Survival ofLeishmaniaSpecies That Cause Visceral Leishmaniasis Is Significantly Reduced by HIVâ€1 Protease Inhibitors. Journal of Infectious Diseases, 2008, 198, 1292-1299.	1.9	64
27	Leishmania infantumPromastigotes Reduce Entry of HIVâ€1 into Macrophages through a Lipophosphoglycanâ€Mediated Disruption of Lipid Rafts. Journal of Infectious Diseases, 2008, 197, 1701-1708.	1.9	10
28	Consequences of the natural propensity of Leishmania and HIV-1 to target dendritic cells. Trends in Parasitology, 2007, 23, 317-324.	1.5	17
29	Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine, 2006, 24, 1800-1810.	1.7	38
30	Leishmania donovani: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine, 2006, 24, 2900-2909.	1.7	42
31	Animal models for vaccine studies for visceral leishmaniasis. Indian Journal of Medical Research, 2006, 123, 439-54.	0.4	47
32	Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clinical and Experimental Immunology, 2005, 140, 149-156.	1.1	50
33	Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine, 2005, 23, 1189-1196.	1.7	16
34	Efficacy of human Î²-casein fragment (54â€“59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. Peptides, 2004, 25, 1873-1881.	1.2	29
35	Intake of nutrient supplements affects multiplication ofLeishmania donovaniin hamsters. Parasitology, 2004, 129, 685-691.	0.7	23